NASDAQ:MGEN - Miragen Therapeutics News Headlines

Sign in or create an account to add this stock to your watchlist.
$3.49 +0.08 (+2.35 %)
(As of 03/22/2019 04:21 AM ET)
Previous Close$3.41
Today's Range$3.40 - $3.80
52-Week Range$2.20 - $8.20
Volume392,900 shs
Average Volume221,031 shs
Market Capitalization$107.91 million
P/E Ratio-3.17
Dividend YieldN/A
Beta1.21

Headlines

Miragen Therapeutics (NASDAQ MGEN) News Headlines

Source:
DateHeadline
Miragen Therapeutics Inc Expected to Earn Q1 2019 Earnings of ($0.38) Per Share (MGEN)Miragen Therapeutics Inc Expected to Earn Q1 2019 Earnings of ($0.38) Per Share (MGEN)
www.americanbankingnews.com - March 21 at 8:47 AM
Miragen Therapeutics Inc (MGEN) Expected to Earn Q1 2020 Earnings of ($0.45) Per ShareMiragen Therapeutics Inc (MGEN) Expected to Earn Q1 2020 Earnings of ($0.45) Per Share
www.americanbankingnews.com - March 20 at 7:38 AM
Wedbush Reiterates Outperform Rating for Miragen Therapeutics (MGEN)Wedbush Reiterates Outperform Rating for Miragen Therapeutics (MGEN)
www.americanbankingnews.com - March 18 at 8:53 AM
Miragen Therapeutics (MGEN) Posts Quarterly  Earnings Results, Misses Expectations By $0.02 EPSMiragen Therapeutics (MGEN) Posts Quarterly Earnings Results, Misses Expectations By $0.02 EPS
www.americanbankingnews.com - March 14 at 8:45 AM
miRagen Therapeutics, Inc. (MGEN) CEO William Marshall on Q4 2018 Results - Earnings Call TranscriptmiRagen Therapeutics, Inc. (MGEN) CEO William Marshall on Q4 2018 Results - Earnings Call Transcript
seekingalpha.com - March 14 at 5:13 AM
miRagen Announces Fourth Quarter and Full Year 2018 Financial Results and Provides 2019 OutlookmiRagen Announces Fourth Quarter and Full Year 2018 Financial Results and Provides 2019 Outlook
finance.yahoo.com - March 14 at 5:13 AM
Signal Genetics, Inc. (MGEN) Reports Q4 Loss, Misses Revenue EstimatesSignal Genetics, Inc. (MGEN) Reports Q4 Loss, Misses Revenue Estimates
finance.yahoo.com - March 14 at 5:13 AM
miRagen Therapeutics to Present a Corporate Overview at the 29th Annual Oppenheimer & Co. Healthcare Conference - GlobeNewswiremiRagen Therapeutics to Present a Corporate Overview at the 29th Annual Oppenheimer & Co. Healthcare Conference - GlobeNewswire
globenewswire.com - March 6 at 3:16 PM
miRagen Therapeutics to Present a Corporate Overview at the 29th Annual Oppenheimer & Co. Healthcare ConferencemiRagen Therapeutics to Present a Corporate Overview at the 29th Annual Oppenheimer & Co. Healthcare Conference
finance.yahoo.com - March 6 at 3:16 PM
Miragen Therapeutics Inc (MGEN) Given Consensus Recommendation of "Buy" by BrokeragesMiragen Therapeutics Inc (MGEN) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - March 6 at 9:43 AM
Miragen Therapeutics (MGEN) Set to Announce Earnings on WednesdayMiragen Therapeutics (MGEN) Set to Announce Earnings on Wednesday
www.americanbankingnews.com - March 6 at 1:35 AM
 Analysts Expect Miragen Therapeutics Inc (MGEN) Will Announce Quarterly Sales of $1.54 Million Analysts Expect Miragen Therapeutics Inc (MGEN) Will Announce Quarterly Sales of $1.54 Million
www.americanbankingnews.com - March 2 at 8:12 PM
-$0.31 EPS Expected for Miragen Therapeutics Inc (MGEN) This Quarter-$0.31 EPS Expected for Miragen Therapeutics Inc (MGEN) This Quarter
www.americanbankingnews.com - February 28 at 5:28 AM
miRagen Therapeutics to Report Fourth Quarter and Fiscal 2018 Financial Results and Host a Conference Call on March 13thmiRagen Therapeutics to Report Fourth Quarter and Fiscal 2018 Financial Results and Host a Conference Call on March 13th
finance.yahoo.com - February 20 at 3:10 PM
Colorado biotech firms are developing drugs to fight cancer, help children and cut down on excessive sweatingColorado biotech firms are developing drugs to fight cancer, help children and cut down on excessive sweating
finance.yahoo.com - January 24 at 3:07 PM
MiRagens cobomarsen shows positive action in early-stage blood cancer studiesMiRagen's cobomarsen shows positive action in early-stage blood cancer studies
seekingalpha.com - January 10 at 3:12 PM
miRagen Announces New Clinical Data in Patients With Three Different Types of Blood Cancers Treated With CobomarsenmiRagen Announces New Clinical Data in Patients With Three Different Types of Blood Cancers Treated With Cobomarsen
finance.yahoo.com - January 10 at 3:12 PM
Miragen Therapeutics Inc.Miragen Therapeutics Inc.
www.barrons.com - January 4 at 3:17 PM
miRagen Therapeutics to Present New Cobomarsen Clinical Trial Data for Adult T-Cell Leukemia/Lymphoma and Cutaneous T-Cell Lymphoma at the 11th Annual T-Cell Lymphoma ForummiRagen Therapeutics to Present New Cobomarsen Clinical Trial Data for Adult T-Cell Leukemia/Lymphoma and Cutaneous T-Cell Lymphoma at the 11th Annual T-Cell Lymphoma Forum
finance.yahoo.com - December 20 at 3:13 PM
Hedge Funds Are Crazy About Miragen Therapeutics, Inc. (MGEN)Hedge Funds Are Crazy About Miragen Therapeutics, Inc. (MGEN)
finance.yahoo.com - December 18 at 3:05 PM
miRagen Therapeutics Announces Board of Director Evolution and Appointment of New ChairmanmiRagen Therapeutics Announces Board of Director Evolution and Appointment of New Chairman
finance.yahoo.com - December 6 at 5:16 AM
Form 8-K MIRAGEN THERAPEUTICS, For: Dec 02 - StreetInsider.comForm 8-K MIRAGEN THERAPEUTICS, For: Dec 02 - StreetInsider.com
www.streetinsider.com - December 5 at 3:14 PM
miRagen Therapeutics Announces Final Safety, Biodistribution and Clinical Efficacy Data From PhasemiRagen Therapeutics Announces Final Safety, Biodistribution and Clinical Efficacy Data From Phase
www.nasdaq.com - December 3 at 5:16 AM
Miragen Therapeutics, Inc. (MGEN) CEO William Marshall on Q3 2018 Results - Earnings Call TranscriptMiragen Therapeutics, Inc. (MGEN) CEO William Marshall on Q3 2018 Results - Earnings Call Transcript
seekingalpha.com - November 10 at 5:15 AM
Form 10-Q MIRAGEN THERAPEUTICS, For: Sep 30Form 10-Q MIRAGEN THERAPEUTICS, For: Sep 30
www.streetinsider.com - November 9 at 3:14 PM
miRagen Therapeutics Reports Third Quarter 2018 Financial Results and Provides Corporate UpdatemiRagen Therapeutics Reports Third Quarter 2018 Financial Results and Provides Corporate Update
finance.yahoo.com - November 8 at 5:37 AM
Signal Genetics, Inc. (MGEN) Reports Q3 Loss, Misses Revenue EstimatesSignal Genetics, Inc. (MGEN) Reports Q3 Loss, Misses Revenue Estimates
finance.yahoo.com - November 8 at 5:37 AM
Miragen Therapeutics to Present New Cobomarsen Phase 1 Clinical Trial Data at the 2018 American Society of Hematology Annual MeetingMiragen Therapeutics to Present New Cobomarsen Phase 1 Clinical Trial Data at the 2018 American Society of Hematology Annual Meeting
finance.yahoo.com - November 1 at 3:08 PM
miRagen Therapeutics to Present at two Investor Conferences in November 2018miRagen Therapeutics to Present at two Investor Conferences in November 2018
finance.yahoo.com - October 29 at 9:35 AM
miRagen Therapeutics to Report Third Quarter 2018 Financial Results and Host Conference Call on November 7, 2018miRagen Therapeutics to Report Third Quarter 2018 Financial Results and Host Conference Call on November 7, 2018
finance.yahoo.com - October 24 at 3:09 PM
miRagen Therapeutics (MGEN) Highlights Data from Preclinical Studies Demonstrating the Potential Anti-Fibrotic Effect of Remlarsen in the CorneamiRagen Therapeutics (MGEN) Highlights Data from Preclinical Studies Demonstrating the Potential Anti-Fibrotic Effect of Remlarsen in the Cornea
www.streetinsider.com - October 2 at 3:06 PM
miRagen Therapeutics Announces the Presentation of Data From Preclinical Studies Demonstrating the Potential Anti-Fibrotic Effect of Remlarsen in the Cornea at the 2018 OLIGO Meeting in Seattle, WAmiRagen Therapeutics Announces the Presentation of Data From Preclinical Studies Demonstrating the Potential Anti-Fibrotic Effect of Remlarsen in the Cornea at the 2018 OLIGO Meeting in Seattle, WA
finance.yahoo.com - October 1 at 3:02 PM
Miragen Therapeutics (MGEN) Presents At 2018 Wedbush PacGrow Healthcare Conference - SlideshowMiragen Therapeutics (MGEN) Presents At 2018 Wedbush PacGrow Healthcare Conference - Slideshow
seekingalpha.com - August 15 at 3:08 PM
Miragen Therapeutics, Inc. (MGEN) CEO William Marshall on Q2 2018 Results - Earnings Call TranscriptMiragen Therapeutics, Inc. (MGEN) CEO William Marshall on Q2 2018 Results - Earnings Call Transcript
seekingalpha.com - August 8 at 5:11 AM
miRagen Therapeutics Reports Second Quarter 2018 Financial Results and Provides Corporate UpdatemiRagen Therapeutics Reports Second Quarter 2018 Financial Results and Provides Corporate Update
finance.yahoo.com - August 8 at 5:11 AM
miRagen Therapeutics and The Leukemia & Lymphoma Society® Enter Into an Agreement to Facilitate the Development of Cobomarsen in Cutaneous T-Cell LymphomamiRagen Therapeutics and The Leukemia & Lymphoma Society® Enter Into an Agreement to Facilitate the Development of Cobomarsen in Cutaneous T-Cell Lymphoma
finance.yahoo.com - August 6 at 3:06 PM
miRagen Therapeutics to Present at the 2018 Wedbush PacGrow Healthcare ConferencemiRagen Therapeutics to Present at the 2018 Wedbush PacGrow Healthcare Conference
finance.yahoo.com - July 31 at 3:08 PM
miRagen Therapeutics to Report Second Quarter 2018 Financial Results and Host Conference Call on August 7, 2018miRagen Therapeutics to Report Second Quarter 2018 Financial Results and Host Conference Call on August 7, 2018
finance.yahoo.com - July 25 at 3:05 PM
MiRagen launches mid-stage study of MRG-201MiRagen launches mid-stage study of MRG-201
seekingalpha.com - July 10 at 3:12 PM
miRagen Therapeutics Announces Initiation of Phase 2 Clinical Trial of MRG-201miRagen Therapeutics Announces Initiation of Phase 2 Clinical Trial of MRG-201
finance.yahoo.com - July 10 at 3:12 PM
Gaithersburg biotech raising $1M to stop cancer tumors in their tracksGaithersburg biotech raising $1M to stop cancer tumors in their tracks
finance.yahoo.com - July 3 at 3:05 PM
Miragen Therapeutics to Present First Cobomarsen Phase 1 Clinical Trial Data From Patients With Adult T-Cell Leukemia/lymphoma and New Interim Data From Patients With Mycosis Fungoides at the 2018 American Society of Clinical Oncology Annual MeetingMiragen Therapeutics to Present First Cobomarsen Phase 1 Clinical Trial Data From Patients With Adult T-Cell Leukemia/lymphoma and New Interim Data From Patients With Mycosis Fungoides at the 2018 American Society of Clinical Oncology Annual Meeting
finance.yahoo.com - June 4 at 3:05 PM
miRagen Therapeutics to Present at Jefferies 2018 Global Healthcare Conference on Thursday, June 7thmiRagen Therapeutics to Present at Jefferies 2018 Global Healthcare Conference on Thursday, June 7th
finance.yahoo.com - May 31 at 3:01 PM
Miragen Therapeutics (MGEN) Presents At 2018 UBS Global Healthcare Conference - SlideshowMiragen Therapeutics (MGEN) Presents At 2018 UBS Global Healthcare Conference - Slideshow
seekingalpha.com - May 25 at 3:12 PM
miRagen Therapeutics (MGEN) to Present New Interim Data From Phase 1 Clinical Trial of Cobomarsen at ASCOmiRagen Therapeutics (MGEN) to Present New Interim Data From Phase 1 Clinical Trial of Cobomarsen at ASCO
www.streetinsider.com - May 18 at 5:04 AM
miRagen Therapeutics to Present New Interim Data From Phase 1 Clinical Trial of Cobomarsen at the 2018 American ...miRagen Therapeutics to Present New Interim Data From Phase 1 Clinical Trial of Cobomarsen at the 2018 American ...
globenewswire.com - May 18 at 5:04 AM
FDA Thumbs-Down Makes EOLS Frown, IMMU Up On Breast Cancer Data, MGEN On WatchFDA Thumbs-Down Makes EOLS Frown, IMMU Up On Breast Cancer Data, MGEN On Watch
www.nasdaq.com - May 17 at 5:31 AM
miRagen Therapeutics to Present New Interim Data From Phase 1 Clinical Trial of Cobomarsen at the 2018 American Society of Clinical Oncology Annual MeetingmiRagen Therapeutics to Present New Interim Data From Phase 1 Clinical Trial of Cobomarsen at the 2018 American Society of Clinical Oncology Annual Meeting
finance.yahoo.com - May 17 at 5:31 AM
miRagen Therapeutics (MGEN) CEO William Marshall on Q1 2018 Results - Earnings Call TranscriptmiRagen Therapeutics' (MGEN) CEO William Marshall on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 10 at 5:01 AM
miRagen Therapeutics Reports First Quarter 2018 Financial Results and Provides Corporate UpdatemiRagen Therapeutics Reports First Quarter 2018 Financial Results and Provides Corporate Update
finance.yahoo.com - May 10 at 5:01 AM
This page was last updated on 3/22/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel